



REMARKS


In view of the restriction required by the Examiner in parent application Serial No. 10/090,288, filed March 4, 2002, Applicants herein elect to prosecute claims directed to compounds of formula (I):



Wherein E is a group of the following formula:



Applicants provisionally elect the following ultimate specie:



which is the compound of Example 201.

The presently elected compounds have substantially the same Group I core designated by the Examiner in the parent application (i.e. E = E₁, r and s are 0, R₈ and R₉ are not both hydrogen, X is a Nitrogen). However, the present R₂ and/or G variables reflect original scope of those variables, excepting those members of the R₂ and G Markush groups that have already been prosecuted to allowance in the parent application. Accordingly, claims 1 – 10, 12, 14, and 16 – 19 (as amended herein) read on the remainder

of the Group I core invention that Applicants wish to pursue in this divisional application. Applicants reserve the right to prosecute the remainder of the invention pursuant to rejoinder or in divisional or continuation application(s).

Applicants believe that the amended claims are in condition for allowance.

Respectfully submitted,

Bristol-Myers Squibb Company

Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5323

A handwritten signature in cursive script, appearing to read "Laurelee A. Duncan", written over a horizontal line.

Laurelee A. Duncan
Attorney for Applicants
Reg. No. 44,096

Date: October 29, 2003